Ori­gi­nal-Re­se­arch: DN Group AG (by GBC AG): Buy

Re­se­arch | 10 No­vem­ber 2026 09​:30

Ori­gi­nal-Re­se­arch: DN Group AG – from GBC AG

10.11.2026 / 09​:30 CET/CEST
Dis­se­mi­na­ti­on of a Re­se­arch, trans­mit­ted by EQS News– a ser­vice of EQS Group.
The is­suer is so­le­ly re­spon­si­ble for the con­tent of this re­se­arch. The re­sult of this re­se­arch does not con­sti­tu­te in­vest­ment ad­vice or an in­vi­ta­ti­on to con­clude cer­tain stock ex­ch­an­ge tran­sac­tions.


Clas­si­fi­ca­ti­on of GBC AG to DN Group AG

Com­pa­ny Name: DN Group AG
ISIN: DE000A3DW408
Re­ason for the re­se­arch: Re­se­arch Note
Re­com­men­da­ti­on: BUY
Tar­get pri­ce: 6.85 EUR
Tar­get pri­ce on sight of: 31.12.2027
Last ra­ting ch­an­ge:
Ana­lyst: Cos­min Fil­ker, Mar­cel Gold­mann

Ope­ra­tio­nal suc­ces­ses achie­ved at port­fo­lio com­pa­nies; bond is­sue with a vo­lu­me of up to €125 mil­li­on; Ra­ting: BUY

DN Group AG has con­sis­t­ent­ly rea­li­gned its busi­ness mo­del towards im­pact in­ves­t­ing sin­ce 2024. The com­pa­ny fo­cu­ses on in­vest­ments in busi­nesses ope­ra­ting in fu­ture-ori­en­ted sec­tors such as AI, mo­bi­li­ty, the cir­cu­lar eco­no­my, food, he­alth­ca­re and en­er­gy, which are ex­pec­ted to com­bi­ne eco­no­mic va­lue crea­ti­on po­ten­ti­al with a po­si­ti­ve con­tri­bu­ti­on to the en­vi­ron­ment or so­cie­ty. The sel­ec­tion of new in­vest­ments is ba­sed on an In­vest­ment Frame­work ad­opted in May 2025. Un­der this frame­work, at least 80% of the in­vest­ment vo­lu­me is to be al­lo­ca­ted to com­pa­nies with a me­a­sura­ble po­si­ti­ve im­pact. Po­ten­ti­al in­vest­ments are as­ses­sed against ex­clu­si­on cri­te­ria, their con­tri­bu­ti­on to the UN Sus­tainable De­ve­lo­p­ment Goals and as part of an ESG im­pact due di­li­gence pro­cess. At the same time, DN Group aims to sup­port its port­fo­lio com­pa­nies in their ope­ra­tio­nal de­ve­lo­p­ment and in ac­ces­sing the ca­pi­tal mar­kets.

Se­ve­ral im­portant de­ve­lo­p­ment mi­le­sto­nes have been achie­ved wi­thin the in­vest­ment port­fo­lio in re­cent months. Of par­ti­cu­lar im­portance is the sta­ke ac­qui­red in Al­ge­ne Hol­ding SE at the end of 2025. The tran­sac­tion was struc­tu­red as a share swap in­vol­ving More Im­pact AG and the­r­e­fo­re did not re­sult in a cash out­flow for DN Group. Al­ge­ne fo­cu­ses on the in­dus­tri­al pro­duc­tion of mi­cro­al­gae, which can be used to pro­du­ce pro­te­ins, fat­ty acids, vit­amins and pig­ments, among other pro­ducts. Fol­lo­wing suc­cessful ups­ca­ling, se­ries pro­duc­tion of high-pu­ri­ty mi­cro­al­gae com­men­ced in July 2026, with an in­iti­al har­ve­st of 4,500 li­t­res. Al­ge­ne also re­cei­ved GMP cer­ti­fi­ca­ti­on, ther­eby crea­ting im­portant pre­re­qui­si­tes for sup­p­ly­ing cus­to­mers in the cos­me­tics and food in­dus­tries. In ad­di­ti­on, preli­mi­na­ry re­sults from a joint stu­dy with the Tech­ni­cal Uni­ver­si­ty of Mu­nich in­di­ca­te a po­ten­ti­al ap­pli­ca­ti­on of spi­ru­li­na mi­cro­al­gae as a feed in­gre­di­ent in shrimp far­ming. Fi­nal stu­dy re­sults are ex­pec­ted in No­vem­ber 2026.

Pro­gress has also been made at other port­fo­lio com­pa­nies. At SW Save The Wa­ter Hol­ding AG, in which DN Group has held a 9.5% sta­ke sin­ce May 2025, the fo­cus is on the mar­ket launch of the wa­ter­less soap “So­apeya”. The pro­duct re­cei­ved a po­si­ti­ve Der­ma­test as­sess­ment and was used in a hu­ma­ni­ta­ri­an aid de­ploy­ment in Sy­ria du­ring sum­mer 2026. In ad­di­ti­on, DN Group ac­qui­red a 20% sta­ke in WINDWISE in March 2026. The com­pa­ny de­ve­lo­ps base-load-op­ti­mi­sed wind tur­bi­nes ba­sed on its pa­ten­ted Ma­x­Cap tech­no­lo­gy and plans to build more than 100 tur­bi­nes by 2030. DN Group is also pro­vi­ding stra­te­gic sup­port to WINDWISE in con­nec­tion with its plan­ned con­ver­si­on into a stock cor­po­ra­ti­on.

The first half of 2026 was pri­ma­ri­ly cha­rac­te­ri­sed by the con­tin­ued fi­nan­cing and ope­ra­tio­nal de­ve­lo­p­ment of the port­fo­lio com­pa­nies. Sin­ce the be­gin­ning of the year, DN Group has pro­vi­ded di­rect and in­di­rect port­fo­lio com­pa­nies with lo­ans to­tal­ling €6.73 mil­li­on. At DN Group le­vel, to­tal in­co­me de­cli­ned to €7.93 mil­li­on from €13.24 mil­li­on in the pri­or-year pe­ri­od, main­ly due to lower in­co­me from se­cu­ri­ties dis­po­sals. Other ope­ra­ting in­co­me of €4.57 mil­li­on in­cluded €3.61 mil­li­on from the dis­po­sal of shares in Glo­bal He­alth Care AG. In ad­di­ti­on, con­sul­tancy ser­vices of €2.80 mil­li­on had been ren­de­red but not yet in­voi­ced. Due to hig­her bond lia­bi­li­ties, in­te­rest ex­pen­ses in­creased to €3.34 mil­li­on, while pro­fit af­ter tax de­cli­ned to €0.38 mil­li­on from €3.49 mil­li­on in the pre­vious year. It should be no­ted that DN Group’s HGB re­sults only re­flect the ope­ra­ting per­for­mance of the non-con­so­li­da­ted port­fo­lio com­pa­nies to a li­mi­t­ed ext­ent. Equi­ty re­main­ed at a high le­vel of €386.90 mil­li­on.

To fi­nan­ce the fur­ther ex­pan­si­on of the port­fo­lio, the 2026⁄2033 cor­po­ra­te bond with a to­tal vo­lu­me of up to €125 mil­li­on is curr­ent­ly be­ing pla­ced. The bond car­ri­es a cou­pon of 10.0% p​.​a. In the event of a full cash pla­ce­ment, 85% of the net is­sue pro­ceeds are in­ten­ded to be in­ves­ted in exis­ting or new port­fo­lio com­pa­nies, with the re­mai­ning 15% al­lo­ca­ted to DN Group’s working ca­pi­tal. This pro­vi­des ad­di­tio­nal fi­nan­cial fle­xi­bi­li­ty for the fur­ther de­ve­lo­p­ment of the in­vest­ment port­fo­lio.

We con­ti­nue to va­lue DN Group using a NAV ap­proach. Ba­sed on the as­sets re­por­ted as of 30 June 2026 and ta­king into ac­count the hig­her le­vel of fi­nan­cial debt, we de­ri­ve a to­tal NAV of €380.50 mil­li­on (pre­vious­ly: €383.63 mil­li­on), cor­re­spon­ding to €6.85 per share (pre­vious­ly: €6.90). Com­pared with our pre­vious re­se­arch re­port da­ted 11 June 2026, the to­tal NAV has de­cli­ned slight­ly due to the hig­her le­vel of fi­nan­cial debt. Ba­sed on the cur­rent share pri­ce of €5.40, we as­sign a BUY ra­ting.

You can down­load the re­se­arch here: 20261110_DN_Note_en

Cont­act for ques­ti­ons:
GBC AG
Hal­der­stra­ße 27
86150 Augs­burg
0821⁄241133 0
research@​gbc-​ag.​de

++++++++++++++++
Dis­clo­sure of po­ten­ti­al con­flicts of in­te­rest pur­su­ant to Sec­tion 85 of the Ger­man Se­cu­ri­ties Tra­ding Act (WpHG) and Ar­tic­le 20 of the Mar­ket Ab­u­se Re­gu­la­ti­on (MAR). The fol­lo­wing po­ten­ti­al con­flict of in­te­rest exists in re­la­ti­on to the com­pa­ny ana­ly­sed abo­ve: (5a,11). A list of po­ten­ti­al con­flicts of in­te­rest can be found at: https://​www​.gbc​-ag​.de/de​/Offenlegung

Note on is­suer-spon­so­red re­se­arch: This re­se­arch re­port is is­suer-spon­so­red re­se­arch and has been pre­pared in ac­cordance with the EU Code of Con­duct for is­suer-spon­so­red re­se­arch.
+++++++++++++++
Com­ple­ti­on: 09.11.2026 (4​:15 pm)
First dis­tri­bu­ti­on: 10.11.2026 (09​:30 am)

GBC AG
Hal­der­stra­ße 27
86150 Augs­burg

Te­le­fon: +49 821 241133–0
E‑mail: office(@)gbc-ag.de